Pulmonary Hypertension

Nanoparticle-Mediated Delivery of Nuclear Factor κB Decoy Into Lungs Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension

Satoshi Kimura, Kensuke Egashira, Ling Chen, Kaku Nakano, Eiko Iwata, Miho Miyagawa, Hiroyuki Tsujimoto, Kaori Hara, Ryuichi Morishita, Katsuo Sueishi, Ryuji Tominaga, Kenji Sunagawa

Abstract—Pulmonary arterial hypertension (PAH) is an intractable disease of the small pulmonary artery that involves multiple inflammatory factors. We hypothesized that a redox-sensitive transcription factor, nuclear factor κB (NF-κB), which regulates important inflammatory cytokines, plays a pivotal role in PAH. We investigated the activity of NF-κB in explanted lungs from patients with PAH and in a rat model of PAH. We also examined a nanotechnology-based therapeutic intervention in the rat model. Immunohistochemistry results indicated that the activity of NF-κB increased in small pulmonary arterial lesions and alveolar macrophages in lungs from patients with PAH compared with lungs from control patients. In a rat model of monocrotaline-induced PAH, single intratracheal instillation of polymeric nanoparticles (NPs) resulted in delivery of NPs into lungs for ≥14 days postinstillation. The NP-mediated NF-κB decoy delivery into lungs prevented monocrotaline-induced NF-κB activation. Blockade of NF-κB by NP-mediated delivery of the NF-κB decoy attenuated inflammation and proliferation and, thus, attenuated the development of PAH and pulmonary arterial remodeling induced by monocrotaline. Treatment with the NF-κB decoy NP 3 weeks after monocrotaline injection improved the survival rate as compared with vehicle administration. In conclusion, these data suggest that NF-κB plays a primary role in the pathogenesis of PAH and, thus, represent a new target for therapeutic intervention in PAH. This nanotechnology platform may be developed as a novel molecular approach for treatment of PAH in the future. (Hypertension. 2009;53:877-883.)

Key Words: pulmonary hypertension • lung • inflammation • leukocytes

Pulmonary arterial hypertension (PAH) is an intractable disease of the small pulmonary arteries that results in a progressive increase in pulmonary vascular resistance, right ventricular failure, and, ultimately, premature death.1–5 Because its mortality remains high even after the introduction of prostacyclin infusion therapy (which has raised the 5-year survival rate to ≈50%), the development of a more effective and less invasive therapy for PAH is urgently needed.

Recent evidence suggests an important role of monocyte chemoattractant protein (MCP) 1–mediated inflammation in the mechanism of PAH.6–8 However, the therapeutic benefits of MCP-1 blockade were not optimal for clinical application.9,10 During the inflammatory process of PAH, several inflammatory factors (eg, MCP-1, interleukin [IL] 1, IL-6, and tumor necrosis factor [TNF] α) are overproduced, leading to a vicious circle.1–3 A redox-sensitive transcription factor, nuclear factor κB (NF-κB), is known to regulate expression of chemokines such as MCP-1 and multiple inflammatory cytokines such as IL-6 and TNF-α. Blockade of NF-κB by transfection of NF-κB “decoy” oligodeoxynucleotides may attenuate the vascular pathology associated with reduced expression of NF-κB–dependent genes.9–12 However, no previous study has addressed the specific role of the NF-κB pathway in the pathogenesis of PAH. Therefore, we hypothesized that controlled local delivery of NF-κB decoy into lungs, targeting a battery of multiple important inflammatory cytokines, would be a favorable therapeutic approach for PAH. To this end, we have recently developed bioabsorbable polymeric nanoparticles (NPs) formulated from a poly-(ethylene glycol)-block-lactide/glycolide copolymer (PEG-PLGA).13–15

The primary aim of this study was to investigate the role of the NF-κB pathway in the pathogenesis of PAH. We first examined the activity of NF-κB in patients with PAH. We then used a rat model of monocrotaline (MCT)-induced PAH to examine whether NP-mediated delivery of the NF-κB decoy can attenuate the development of PAH.

Methods

Histopathologic and Immunohistochemical Examination of Human Lungs

Human lung tissue was obtained from autopsy specimens from 4 patients whose deaths were attributed to idiopathic PAH and 2
patients whose deaths were attributed to nonlung disease (Figure S1, available in the online data supplement at http://hyper.ahajournals.org). Additional details are provided in the online data supplement.

Preparation of NPs

The NF-κB decoy oligodeoxynucleotides labeled with or without fluorescein-isothiocyanate (FITC) were prepared as described previously.10,11 The decoy is directed against the NF-κB binding site in the promoter region that corresponds with NF-κB-responsive genes and works to inhibit binding of this transcription factor to the promoter region.10,11 PEG-PLGA NPs encapsulated with FITC, NF-κB decoy, or FITC-labeled NF-κB decoy were prepared using an emulsion solvent diffusion method.13,14 The average diameter of PEG-PLGA NPs was 44 nm. To measure FITC release kinetics, FITC-NP was immersed in Tris-EDTA buffer, and the released FITC was measured. Additional details are provided in the online data supplement.

In Vivo Experiments With a Rat Model of MCT-Induced PAH

Rats were SC injected with 60 mg/kg of MCT, which induces severe PAH within 3 weeks.5,15,16 In the prevention protocol, animals were assigned to either an untreated control group or a group that received a single intratracheal instillation of NF-κB decoy alone (50 μg), FITC-NP (1000 μg of PEG-PLGA), or NF-κB decoy NPs (50 μg of NF-κB decoy per 1000 μg of PEG-PLGA) immediately after MCT (n=6 each). For intratracheal instillation, a volume of 0.1 mL of phosphate buffer suspension of NP or NF-κB decoy was injected gently into the trachea of animals accompanied by an equal volume of air. The biodistribution of FITC in the lung was also examined 3, 7, and 14 days after intratracheal instillation of FITC only, FITC-NPs, or FITC-labeled NF-κB decoy NPs in rats injected with MCT. In the treatment protocol, rats were divided into 2 groups (rats treated with a single intratracheal instillation of phosphate buffer and rats treated with NF-κB decoy NPs; n=33 each) 21 days after MCT injection, when severe PAH had been established.

Histopathologic and Immunohistochemical Analysis

The degrees of monocyte infiltration were evaluated by immunostaining with the ED-1 (analogue of human CD68) antibody against monocytes. For quantification, a blind observer counted the number of ED-1–positive cells in 10 fields.4 Monocytes were also subjected to immunostaining with antibodies against FITC, an epitope (α-p65) on the p65 subunit of NF-κB, or nonimmune mouse IgG. The α-p65 monoclonal antibody recognizes an epitope on the p65 subunit that is masked by bond inhibitor of κB (I-κB).9 Therefore, this antibody exclusively detects activated NF-κB.12

Electrophoretic Mobility-Shift Assays

Nuclear extracts were prepared from the whole-lung homogenates using a nuclear extract kit (NE-PER Nuclear and Cytoplasmic Extraction Reagents, Thermo Science) according to the manufacturer’s instructions. The protein was measured using a BCA Protein Assay kit (Thermo Science). For NF-κB activation, a nonradioactive electrophoresis mobility-shift assay kit (AY1030, Panomics) was used according to the manufacturer’s instructions. Five μg of nuclear protein were incubated for 30 minutes at room temperature with a biotinylated oligonucleotide containing the NF-κB binding site, and then the samples were separated on a nondenaturing polyacrylamide gel and blotted onto a positively charged nylon membrane. After blotting, the oligos on the membrane were fixed using a UV cross-linker oven. Then, the membrane was incubated with streptavidin-horseradish-peroxidase solution at room temperature for 15 minutes and with detection reagents for 5 minutes. Nuclear proteins that were bound to the NF-κB binding site were detected by chemiluminescence with the use of the LAS-1000 detection system (Fujifilm).

Real-Time Quantitative RT-PCR

Real-time PCR amplification was performed with the rat cDNA with the use of the ABI PRISM 7000 Sequence Detection System (Applied Biosystems), as described previously.17 TaqMan primer/probes for MCP-1, TNF-α, IL-1, IL-6, intercellular adhesion molecule 1, and GAPDH, which served as the endogenous reference, were purchased from Applied Biosystems (Assay-on-Demand gene expression products Rn00580555, Rn099999017, Rn00580432, Rn00561420, and Rn00564227 and TaqMan Rodent GAPDH Control Reagents, respectively).

Intracellular Delivery of NPs Incorporated With an FITC-Labeled NF-κB Decoy to Human Monocytes and Pulmonary Arterial Smooth Muscle Cells

The human monocyte cell line THP-1 was obtained from the German Collection of Micro-organisms and Cell Cultures and was used between passages 4 and 8. Cells were cultured in RPMI 1640 with 10% FBS in a humidified atmosphere of 5% CO₂ in air. The cell density was adjusted to 10⁶ cells per milliliter in 1 mL of serum-free medium in 35-mm-diameter dishes. The cells were serum deprived 24 hours before the experiment. The growth medium was replaced with FITC-conjugated NF-κB decoy encapsulated PEG-PLGA NP suspension medium (0.5 mg/mL) and then further incubated for 1 hour. At the end of the experiment, the cells were washed 3 times with PBS to eliminate excess NPs that were not incorporated into the cells. Then, the cells were fixed with 10% cold methanol, and nuclei were counterstained with propidium iodide. Cellular uptake of FITC-conjugated NF-κB decoy-encapsulated PEG-PLGA NPs was evaluated by fluorescence microscopy.

Human pulmonary artery smooth muscle cells (PASMCs) were obtained from Cambrex Bio Science, Inc, and cultured as described previously. Cells were used between passages 4 and 8. Human PASMCs were seeded on chambered cover glasses and incubated at 37°C/5% CO₂ until the cells were subconfluent. The following treatments were performed in the same manner.
Lipopolysaccharide-Induced Activation of Human Monocytes

Bacterial lipopolysaccharide (serotype 0111:B4; Sigma) was added at 1 μg/mL to the cells as indicated for each experiment. NF-κB decoy at 5 μg/mL, NF-κB decoy-encapsulated NPs containing 0.1 mg/mL of PEG-PLGA NP and 5 μg/mL of NF-κB decoy, or the vehicle alone was added to the wells simultaneously. Four hours later, the cells were washed 3 times with PBS. NF-κB pathway activity was measured using a TransAM NF-κB p65 ELISA-based assay kit (Active Motif). Nuclear extracts of THP-1 were prepared with the NE-PER kit (Pierce) according to the manufacturer’s protocol. All of the procedures were carried out at 4°C. Protein concentration was determined by BCA assay, and 20 μg of protein from each sample were used in the assay. Samples were placed along with 30 μL of binding buffer on a 96-well plate to which oligonucleotides containing an NF-κB consensus binding site had been immobilized. Plates were incubated for 1 hour on a shaker. During this time, the activated NF-κB contained in the sample specifically bound to this nucleotide. The plate was then washed, and the NF-κB complex bound to the oligonucleotides was detected using a primary antibody (100 μL diluted 1:1000 in antibody binding buffer for 1 hour) that is directed against the NF-κB p65 subunit. The plate was then washed again, 100 μL of secondary antibody (diluted 1:1000 in antibody binding buffer) conjugated to horseradish peroxidase was added, and the plate was incubated for 1 hour. The plate was washed again, and 100 μL of developing solution were added. The plate was incubated for 4 minutes away from direct light, 100 μL of stop solution were added, and the plate was read using a plate reader at 450 nm.

Human PASMC Proliferation Assay

Human PASMCs were seeded on 96-well culture plates at 1×10^4 cells per well (n=6 per group) in smooth muscle cells–basal medium with 10% FBS. After 24 hours, the cells were starved for 48 hours in serum-free medium to obtain quiescent nondividing cells. After starvation, 10% FBS was added. Also, a concentration of 1 mg/mL of NF-κB decoy only, NF-κB decoy-encapsulated PEG-PLGA NPs (0.05 mg/mL of PEG-PLGA and 1 mg/mL of decoy), or FITC-encapsulated PEG-PLGA NPs was added to each well. Cells were incubated for another 24 hours after addition of 5′-bromo-2′-deoxyuridine. 5′-Bromo-2′-deoxyuridine incorporation was evaluated by an ELISA kit from Calbiochem.

Statistical Analysis

All of the results are expressed as the mean±SEM. Statistical analysis of differences was performed by ANOVA followed by Bonferroni’s multiple comparison test. The survival rates were determined by the Kaplan–Meier method. *<0.05 was considered statistically significant.

Results

Activation of NF-κB Expression in Patients With PA6H and in MCT-Induced PAH Rats

Localization of NF-κB activation was examined by immuno-histochemical studies in lung tissue from patients using the antibody against α-p65.9 An intense immunoreactivity of α-p65 was noted primarily in alveolar macrophages and to some extent in small pulmonary arterial lesions (mainly in smooth muscle cells in the medium) from 4 patients with PAH (Figure 1A and Figure S1A). This NF-κB activation was associated with positive staining of MCP-1 and IL-6. In contrast, none at all of α-p65 was detected in 2 control patients whose deaths were not attributed to lung disease (Figure S1B).

In MCT-induced PAH rats, activation NF-κB was noted mainly in alveolar macrophages and weakly in pulmonary artery lesions 7 days after MCT administration (Figure 1B and 1C). An electrophoretic mobility-shift assay was performed to detect the DNA binding activity of NF-κB (Figure S2). The binding activity of the lung increased in rats after MCT injection, which peaked on day 3 and decreased on day 7.

Effects of Intratracheal Treatment With NF-κB Decoy NP on NF-κB Activation

Single intratracheal instillation of NF-κB decoy NPs on NF-κB activation in rats. A, Micrographs of cross sections of the lung from patient 1 stained immunohistochemically with NF-κB (α-p65), MCP-1, and IL-6. Pictures stained with nonimmune IgG control are shown in the inset. Scale bar: 50 μm. B, Micrographs of cross sections of the lung stained immunohistochemically with NF-κB (α-p65) from normal rats and PAH rats 7 days after MCT injection. Scale bar: 50 μm. C, Effects of NF-κB decoy NPs on infiltration of NF-κB (α-p65)-positive cells 7 days after MCT injection. Data are mean±SEM (n=4 each). *P<0.01 vs PBS vs normal control.
As reported previously by us and by other investigators,5,16,17 the injection of MCT results in severe PAH (increased RV systolic pressure and RV hypertrophy; Figure 3) associated with small pulmonary arterial remodeling (Figure 4) and increased infiltration of ED-1–positive monocytes (Figure 4) 3 weeks after MCT injection. Single intratracheal treatment with NF-κB decoy NPs but not with NF-κB decoy only or FITC-NPs attenuated the development of PAH (Figure 3), small pulmonary arterial remodeling (Figure 4), and inflammation (Figure 4).

Effects of NF-κB Decoy NPs on Expression of Proinflammatory Factors
As reported previously,3,4 MCT-induced PAH was associated with increased gene expression of proinflammatory factors. Treatment with NF-κB decoy NPs significantly reduced the increased gene expression of MCP-1, TNF-α, and IL-1β (Figure 5). NF-κB decoy NPs tended to decrease the expression of IL-6 and intercellular adhesion molecule-1.

In Vitro NP Release Kinetics
An analysis of the in vitro FITC release kinetics from FITC-NP showed an early burst of FITC release such that ≈40% of the total amount ultimately released was present on day 1, followed by sustained release of the remaining FITC over the next 28 days (Figure S4).

Effects of NF-κB Decoy NPs on Survival
Treatment with NF-κB decoy NPs 21 days after MCT injection significantly (P<0.01) improved the survival rate (Figure 6).
Discussion

The present study demonstrates for the first time that intratracheal instillation of PEG-PLGA NPs is an excellent system for drug delivery of NF-κB decoy to the lung. The FITC signals were detected not only in small bronchial tracts but also in alveolar macrophages and small pulmonary arteries for ≤14 days after a single instillation. After cellular uptake of NPs, NPs might slowly release encapsulated decoy into the cytoplasm as PLGA is hydrolyzed. This might protect the encapsulated decoy from intracellular degradation before its arrival at the nuclear target. Our in vitro studies in cultured human monocytes and pulmonary arterial smooth muscle cells support this notion. Therefore, this platform nanotechnology may represent a novel NP-mediated drug delivery system for treatment of severe lung diseases, including PAH.

The present study also reports a pivotal role of NF-κB in the pathogenesis of PAH. Recently, Sawada et al.19 and Huang et al.20 reported that systemic daily administration of pyrrolidine dithiocarbamate, a nonspecific inhibitor of NF-κB, attenuated the development of MCT-induced PAH. Pyrrolidine dithiocarbamate is known to be a low molecular weight thiol compound and has anti-inflammatory and antioxidant activity independent of the NF-κB pathway. Indeed, in a study by Huang et al.,20 pyrrolidine dithiocarbamate treatment had no effect on MCT-induced NF-κB activation. In contrast, we found in the present study that NF-κB is activated in alveolar macrophages and small pulmonary arteries associated with NF-κB–dependent inflammatory factors (e.g., MCP-1, IL-1, and TNF-α) in patients with PAH and rats with MCT-induced PAH, and blockade of NF-κB activation by a single intratracheal instillation of NF-κB decoy NPs reduced inflammatory changes. These data suggest that NF-κB might be pivotal in mediating inflammatory changes seen in PAH.

We also found that intratracheal instillation of NF-κB decoy NPs prevented the development of PAH (increased RV pressure, RV hypertrophy, and pulmonary artery remodeling) in the prevention protocol. We and others have reported that blockade of MCP-1 reduces vascular pathology after vascular injury21–25 and the development of PAH.5,6 In addition, as we reported in human coronary artery smooth muscle cells in vitro,12,26 we found that NF-κB decoy NPs attenuated proliferation of human PASMCs in vitro. Therefore, the beneficial effects of NF-κB decoy NPs can be attributable to inhibition of inflammation and smooth muscle cell proliferation resulting from reduced NF-κB activation.

Furthermore, we found that a single intratracheal treatment of NF-κB decoy NPs 3 weeks after MCT injection improved survival rate in the treatment protocol, suggesting that this NP-mediated NF-κB decoy delivery may have significant therapeutic effects. We did not examine the therapeutic effects of repetitive intratracheal instillation of NF-κB decoy NPs, because it is technically difficult to perform multiple intratracheal instillation of this NP system in rats and other small animals. For translation of our present findings into clinical medicine, further studies are needed to investigate whether repetitive delivery of NPs into lungs produces greater therapeutic effects over time.

Several points are worth mentioning with regard to potential clinical applicability. First, from a toxicological point of view, no adverse reactions, e.g., pulmonary inflammation, after exposure to a single intratracheal instillation of FITC-NPs (PEG-PLGA at 1 mg per body) or NF-κB decoy NPs (NF-κB decoy at 50 μg per body in rats weighing 250 to 300 g) were noted in the rat model, suggesting that the NPs used in this study may not cause an adverse reaction. However, the 3-week observation period for this NP system might be too short to determine its safety. Second, we reported recently that neither intravenous injection of the NF-κB decoy at 1 mg per body in monkeys nor deployment
of an NF-κB decoy-eluting stent (≈600 μg per stent) in rabbits showed systemic adverse effects. More important are the findings of a clinical trial that we completed recently to test the feasibility and safety of the NF-κB decoy. The decoy was transfected into the stented coronary artery sites at doses of 1000, 2000, or 4000 μg per body via a channel balloon catheter immediately after successful percutaneous coronary intervention in 18 patients with flow-limiting coronary stenosis. The patients showed low restenosis rates and no evidence of systemic adverse effects during the 6-month observation period. These data support the notion that NF-κB decoy can be applied in a clinical setting. Third, this NP system itself is not suitable for inhalant therapy, because it is known that most inhaled NPs are exhaled rather than being delivered into the lung. In contrast, microparticles with aerodynamic diameters between 2 and 8 μm reach small bronchi. However, the microparticles are easily recognized and eliminated by the mucociliary clearance system and alveolar macrophages immediately after they reach the small bronchi. In contrast, polymeric NPs escape the clearance system of the lung when they are delivered into small bronchi and are, thus, taken up by alveoli, macrophages, and pulmonary small vessels. Therefore, to use this NP system for inhalant therapy, we need to develop the nanocomposite microsized particles that will decompose to NPs after reaching the small bronchi.

**Perspectives**

This study has shown that NF-κB is activated in pulmonary arterial lesions in patients with PAH and in rats with MCT-induced PAH, and blockade of NF-κB by NP-mediated NF-κB decoy delivery not only prevented the development of MCT-induced PAH in the prevention protocol but also improved survival rate in the treatment protocol. These data support the notion that NF-κB plays a pivotal role in the pathogenesis of PAH and, thus, represents a new therapeutic target for PAH. This nanotechnology platform may be developed as a more effective and less invasive nanomedicine in PAH therapy.

**Sources of Funding**

This study was supported by Grants-in-Aid for Scientific Research (19390216 and 19650134) from the Ministry of Education, Science, and Culture (Tokyo, Japan) and by Health Science Research grants.
K.E. and R.M. hold a patent on the results reported in this study. The remaining authors report no conflicts.

References


Nanoparticle-Mediated Delivery of Nuclear Factor κB Decoy Into Lungs Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension

Satoshi Kimura, Kensuke Egashira, Ling Chen, Kaku Nakano, Eiko Iwata, Miho Miyagawa, Hiroyuki Tsujimoto, Kaori Hara, Ryuichi Morishita, Katsuo Sueishi, Ryuji Tominaga and Kenji Sunagawa

_Hypertension_. 2009;53:877-883; originally published online March 23, 2009; doi: 10.1161/HYPERTENSIONAHA.108.121418

_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/53/5/877

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2009/03/23/HYPERTENSIONAHA.108.121418.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Hypertension_ is online at:
http://hyper.ahajournals.org/subscriptions/
ONLINE SUPPLEMENT

Nanoparticle-Mediated Delivery of NF-κB Decoy into Lungs Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension

Satoshi Kimura, Kensuke Egashira, Ling Chen, Kaku Nakano, Eiko Iwata, Miho Miyagawa, Hiroyuki Tsujimoto, Kaori Hara, Ryuichi Morishita, Katsuo Sueishi, Ryuji Tominaga, Kenji Sunagawa

Department of Cardiovascular Medicine (KE, LC, KN, EI, MM, K Sunagawa), Surgery (SK, RT), and Pathology (K Sueishi), Graduate School of Medical Science, Kyushu University, Fukuoka, Japan; Hosokawa Powder Technology Research Institute (HT, KH), Osaka, Japan; and Division of Clinical Gene Therapy (RM), Osaka University Medical School, Osaka, Japan.

Address for correspondence:
Kensuke Egashira, MD PhD
Department of Cardiovascular Medicine
Graduate School of Medical Science, Kyushu University
3-1-1, Maidashi, Higashi-ku,
Fukuoka 812-8582, Japan
Phone: +81-92-642-5358
Fax: +81-92-642-5375
E-mail: egashira@cardiol.med.kyushu-u.ac.

Conflict of Interest: Drs. Egashira and Morishita hold a patent on the results reported in this study. The remaining authors report no conflicts.

Online supplement word count (excluding title page): 425
Expanded Materials and Methods

**Histopathological and immunohistochemical examination of human lungs**

Human lung tissue was obtained from autopsy specimens in 4 patients who died due to idiopathic pulmonary arterial hypertension (PAH) and 2 patients died due to non-lung disease (Figure S1). The lung tissues were isolated and fixed with formalin, which were dehydrated, embedded in paraffin, and cut into 5-µm thick slices. The slices were then stained with Hematoxylin and Eosin solution or immunostained with either an epitope (α-p65) on the p65 subunit of nuclear factor-κB (NF-κB) (α-p65, 1:100, Boehringer Mannheim, Roche Diagnostics, Basel, Switzerland), or monocyte chemotractant protein-1 (MCP-1), interleukin (IL)-6 (all from R&D systems) or nonimmune mouse IgG (Dako). This study protocol was approved by the Committee on Ethics on Clinical Study, Kyushu University Faculty of Medicine.

**Preparation of nanoparticles**

The NF-κB decoy oligodeoxynucleotides sequences are 5’-CCTTGAAGGGATTTCCCT-3’ and 3’-GGAACTTCCCTAAAGGGAGG-5’, which are the consensus sequence for the NF-κB binding site. The decoy is directed against the NF-κB binding site in the promoter region that corresponds to NF-κB-responsive genes. The decoy works to inhibit binding of this transcription factor to the promoter region. The NF-κB decoy have been shown to bind to free NF-κB, preventing NF-κB transactivation of the cytokine genes. For trace experiments, fluorescein-isothiocyanate (FITC, Dojindo laboratories, Kumamoto, Japan)-labeled NF-κB decoy was also prepared.

A poly-(ethylene glycol)-block-lactide/glycolide copolymer (PEG-PLGA) was used as a wall material for the NP. The mean particle size was 44 nm with a narrow size distribution (see Figure in this page).
Reference


Patient 2

Alveolar macrophages

pulmonary arterial lesions

Patient 3

Alveolar Macrophages

pulmonary arterial lesions

Patient 4

Alveolar macrophages

pulmonary arterial lesions
### Clinical characteristics of patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Diagnosis</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Duration of Disease (yr)</th>
<th>mean pulmonary artery pressure (mmHg)</th>
<th>treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAH 1</td>
<td>IPAH</td>
<td>35</td>
<td>F</td>
<td>2</td>
<td>48</td>
<td>Beraprost, Bosentan</td>
</tr>
<tr>
<td>PAH 2</td>
<td>IPAH</td>
<td>22</td>
<td>M</td>
<td>2.5</td>
<td>47</td>
<td>Beraprost</td>
</tr>
<tr>
<td>PAH 3</td>
<td>IPAH</td>
<td>14</td>
<td>M</td>
<td>3</td>
<td>50</td>
<td>Beraprost, CCB, HOT</td>
</tr>
<tr>
<td>PAH 4</td>
<td>IPAH</td>
<td>50</td>
<td>F</td>
<td>3</td>
<td>46</td>
<td>PGl2, HOT</td>
</tr>
<tr>
<td>Control1</td>
<td>Sudden death</td>
<td>27</td>
<td>F</td>
<td>-</td>
<td>-</td>
<td>no</td>
</tr>
<tr>
<td>Control2</td>
<td>peritonitis</td>
<td>29</td>
<td>F</td>
<td>-</td>
<td>-</td>
<td>no</td>
</tr>
</tbody>
</table>

**Figure S1. Immunohistochemical detection of activated NF-κB expression in patients with PAH and those with non-pulmonary disease.**

A, Micrographs of cross-sections of the lung from PAH patients 2, 3, and 4 stained immunohistochemically with NF-κB (α-p65), MCP-1, and IL-6. Scale bar = 50 μm

B, Micrographs of cross-sections of the lung from control non-pulmonary disease patients 1 and 2 stained immunohistochemically with NF-κB (α-p65), MCP-1, and IL-6. Scale bar = 50 μm.

C, Clinical characteristics of study patients.

Figure S2. Assessment of DNA binding activity of NF-κB by electrophoretic mobility shift assay.
Lane 1: Labeled probe with no DNA sample. lane 2: Labeled probe with normal lung DNA. Lanes 3, 4, and 5: Labeled probe with lung DNA from PBS-treated animals 1, 3, and 7 days after MCT injection. Lanes 6, 7, and 8: Labeled probe with lung DNA from animals treated with NF-κB decoy NP 1, 3, and 7 days after MCT injection. These DNA binding assay experiments were repeated three times; results from all three trials were similar and representative results are shown.
A THP-1 cells PASMCs

B NF-κB activation in THP-1 cells

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>No Tx</th>
<th>FITC NP</th>
<th>NF-κB decoy</th>
<th>NF-κB decoy NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optical density</td>
<td>NS</td>
<td>NS</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>LPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C Proliferation of human PASMC

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>No Tx</th>
<th>FITC NP</th>
<th>NF-κB decoy</th>
<th>NF-κB decoy NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>% control</td>
<td>NS</td>
<td>NS</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>10 % FBS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* indicates statistical significance at P<0.01 or P<0.001.
Figure S3. *In vitro* cellular uptake of FITC-labeled NF-κB decoy NP and inhibitory effect of NF-κB decoy NP on NF-κB activation of human monocyte cell line (THP-1 cells) and proliferation of human pulmonary artery smooth muscle cells (hPASMC).

A, Fluorescence microscopic pictures of human monocyte cell line (THP-1 cells) and hPASMC incubated with FITC-labeled NF-κB decoy-NP for 60 minutes. Nuclei were counterstained with propidium iodide. Scale bar = 20 μm.

B, Effects of NF-κB decoy-NP on LPS-stimulated activation of NF-κB (ELISA-based DNA binding assay against NF-κB p65 subunit: arbitrary unit) in THP-1 cells. Data are mean ± SEM (*n* = 6 each). *P* < 0.01 versus normal control.

C, Effects of NF-κB decoy NP on FBS-stimulated proliferation of hPASMC (BrdU incorporation index: arbitrary unit). Data are mean ± SEM (*n* = 6 each). *P* < 0.01 versus normal control. Data are percent changes from control (100%).
Figure S4. In vitro time course of cumulative FITC release from the FITC-encapsulated NP (n = 8 each). The percentage of incremental quantities of released FITC was plotted against time.